Since its passage more than two years ago, the Jumpstart Our Business Startups (JOBS) Act, which was designed to decrease regulatory burdens for raising capital, has spurred more than 110 IPOs among biotechnology companies alone. These are companies working to find cures for cancer, cardiovascular disease, blood disorders, and infectious diseases, among other conditions.